Accelerate Diagnostics (AXDX)
(Delayed Data from NSDQ)
$1.93 USD
+0.01 (0.52%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $1.93 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.93 USD
+0.01 (0.52%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $1.93 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum D VGM
Zacks News
Inari Medical, Inc. (NARI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inari Medical (NARI) delivered earnings and revenue surprises of -8.33% and 1.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Accelerate Diagnostics Stock Down Despite FDA Clearance for Arc System
by Zacks Equity Research
AXDX's Arc system gains FDA clearance, automating blood culture prep for faster microbial ID, improved sepsis outcomes and reduced hospital costs.
Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial
by Zacks Equity Research
Accelerate Diagnostics (AXDX) is confident about WAVE product design and the system's capabilities after the successful completion of the pre-clinical trial.
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 9.09% and 0.47%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Silk Road Medical (SILK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of -10.53% and 3.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
InspireMD, Inc. (NSPR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
InspireMD (NSPR) delivered earnings and revenue surprises of -15.79% and 0.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Delcath Systems, Inc. (DCTH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Delcath Systems (DCTH) delivered earnings and revenue surprises of -41.18% and 55.32%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Ekso Bionics (EKSO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -18.18% and 7.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -22.22% and 2.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 0% and 4.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Accelerate Diagnostics (AXDX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Accuray (ARAY) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of -500% and 11.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -43.55% and 20.34%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics
by Zacks Equity Research
Accelerate Diagnostics' (AXDX) Arc system eliminates the need for overnight culture incubation, drastically reducing the wait time for identification results.
Bruker's (BRKR) New Collaboration to Use MALDI Biotyper System
by Zacks Equity Research
Bruker (BRKR) and Accelerate Diagnostics are set to work together to bring rapid, automated microbial identification directly from positive blood culture samples.
Accelerate Diagnostics (AXDX) Loses -25.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Accelerate Diagnostics (AXDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Accelerate Diagnostics (AXDX) Moves 12.7% Higher: Will This Strength Last?
by Zacks Equity Research
Accelerate Diagnostics (AXDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -57.33% and 26.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 57.14% and 39.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Accelerate Diagnostics (AXDX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Accelerate Diagnostics (AXDX) and BellRing Brands (BRBR) have performed compared to their sector so far this year.
Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Akero Therapeutics, Inc. (AKRO) and Accelerate Diagnostics (AXDX) have performed compared to their sector so far this year.
Is Accelerate Diagnostics (AXDX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Accelerate Diagnostics (AXDX) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 0% and 19.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Syneos Health (SYNH) Announces a $7.1 Billion Merger Agreement
by Zacks Equity Research
Syneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium.
Walgreens Boots (WBA) New Alliances Aid Growth, Cost Woe Stays
by Zacks Equity Research
Intensifying competition in the U.S. pharmacy retail drugstore market compels Walgreens Boots (WBA) to diversify its product offerings through new partnerships.